Bristol-Myers AIDS Treatment Cleared

Bristol-Myers ( BMY) was cleared by the Food and Drug Administration to sell a once-daily protease inhibitor that works with other drugs to fight the virus that causes AIDS.

The approval of Reyataz was widely expected after one of the agency's advisory committees reported favorably on it last month. The drug is the first once-daily treatment for AIDS and is also said to not significantly raise cholesterol and triglyceride levels, a common problem with other protease inhibitors.

Bristol-Myers' shares were up 35 cents, or about 1%, to $28.60 in late afternoon trading.

More from Stocks

Bank Stocks Slump After Congress Greenlights Dodd-Frank Rollback

Bank Stocks Slump After Congress Greenlights Dodd-Frank Rollback

10 Questions for PayPal Ahead of Its Big Investor Day

10 Questions for PayPal Ahead of Its Big Investor Day

Stocks Tumble as Trump Comments Lead to Worries Over China Trade Talks

Stocks Tumble as Trump Comments Lead to Worries Over China Trade Talks

Tesla's Model 3 Is Far From Being for the Masses -- at Least For Now

Tesla's Model 3 Is Far From Being for the Masses -- at Least For Now

China Makes Good on Car Tariff Pledge, Tesla Wins Big

China Makes Good on Car Tariff Pledge, Tesla Wins Big